Loxapine succinate - Schizophrenia and other psychoses
You are here : Home > Formulary Search > Loxapine succinate - Schizophrenia and other psychoses
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Loxapine succinate
Indication :
Schizophrenia and other psychoses
Group Name :
Keywords :
antipsychotics
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Loxapine succinate is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Schizophrenia and other psychoses.
Committee Recommendations (2)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The network noted the terminated appraisal TA286 for the use of Loxapine inhalation for schizophrenia or bipolar disorder. The use of this treatment will be considered as BLACK on the PAD please see the policy statement attached.